Hubei Biocause Pharmaceutical Co., Ltd.
Hubei Biocause Pharmaceutical Co., Ltd., commonly referred to as Biocause, is a prominent player in the pharmaceutical industry, headquartered in Hubei, China. Established in 2001, the company has made significant strides in the development and production of high-quality pharmaceutical products, particularly in the fields of antibiotics and anti-infectives. With a strong operational presence across various regions in China and beyond, Biocause is dedicated to innovation and excellence. The company’s core offerings include a diverse range of active pharmaceutical ingredients (APIs) and finished dosage forms, distinguished by their adherence to stringent quality standards and regulatory compliance. Recognised for its commitment to research and development, Hubei Biocause has achieved notable milestones, positioning itself as a trusted partner in the global pharmaceutical market.
DitchCarbon Score
How does Hubei Biocause Pharmaceutical Co., Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Hubei Biocause Pharmaceutical Co., Ltd.'s score of 10 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Hubei Biocause Pharmaceutical Co., Ltd.'s reported carbon emissions
Hubei Biocause Pharmaceutical Co., Ltd., headquartered in China, currently does not have available carbon emissions data for recent years, as no specific emissions figures have been provided. Consequently, there are no documented Scope 1, 2, or 3 emissions to report. In the absence of specific emissions data, it is important to note that the company has not outlined any formal reduction targets or climate commitments. This lack of information suggests that Hubei Biocause may still be in the early stages of developing a comprehensive climate strategy. As the pharmaceutical industry increasingly prioritises sustainability, Hubei Biocause will likely need to establish clear climate commitments and reduction initiatives to align with global standards and expectations.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Hubei Biocause Pharmaceutical Co., Ltd. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
